Sumita Ratnasingam

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

Sumita Ratnasingam, Patricia Walker, Huy Tran et al. · Blood Advances · 2016 · 71 citations · Full text

Proteasome Inhibitors, Immunology, Immunotherapy +17

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Lucy C. Fox, Katherine D. Cummins, Ben Costello et al. · Blood Advances · 2017 · 42 citations · Full text

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, Stephen Opat, Gavin Cull et al. · Blood · 2016 · 36 citations

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

Adrian Minson, Katherine D. Cummins, Lucy C. Fox et al. · Blood Advances · 2019 · 25 citations · Full text

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

Genevieve Douglas, Claire Harrison, Cecily Forsyth et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 16 citations

Hematological Malignancy, Oncology, Hu Intolerance +10